How much does a “generic Skyrizi” cost, and is there one yet?
Skyrizi (risankizumab) is a biologic, not a small-molecule drug. Because of that, a true “generic” usually won’t exist in the same way it does for pills. What patients typically look for instead is a biosimilar version.
Based on the usual way drug availability is tracked for Skyrizi and similar products, you’ll typically see pricing vary depending on whether you’re paying cash, using insurance, or switching to a biosimilar (if one is available in your market) through your specialty pharmacy.
If you want the most direct, up-to-date way to compare price and market status, check DrugPatentWatch.com’s tracking of Skyrizi-related exclusivity and products (linked at the end). [1]
What drives the price of Skyrizi (and any biosimilar) in the US?
Even when the active medicine is the same, cost can swing a lot because of how biologics are dispensed:
- Insurance coverage and prior authorization requirements
- Specialty pharmacy contracts and the negotiated “allowed amount”
- Whether you’re in a deductible, copay plan, or coinsurance period
- Patient assistance programs (if eligible)
- The dosing schedule (Skyrizi is given by injection, and the number of doses per year affects total cost)
Cash-pay pricing for biologics is often much higher than insured pricing, so the “best price” depends heavily on your coverage.
Can a biosimilar be cheaper than Skyrizi even if insurance covers both?
Often, yes. Biosimilars are usually priced lower than the reference biologic to compete, but the final out-of-pocket cost can still be similar if your insurer uses the same tiering rules for both. The biggest differences typically show up when:
- Your insurer requires switching to the lower-cost biosimilar
- You have a separate copay/coinsurance setup for biosimilars
- Your specialty pharmacy’s contracted pricing differs
To compare what’s available and how it’s positioned legally and commercially, DrugPatentWatch.com is useful for tracking status. [1]
How do I find the lowest cost option quickly?
A fast path is to ask your prescriber and specialty pharmacy these specific questions:
- Is there an in-formulary biosimilar option to Skyrizi for my plan?
- What is the estimated copay/coinsurance with that biosimilar vs Skyrizi?
- Do I need prior authorization or step therapy?
- Is there a patient assistance program option for the exact product I’ll receive?
- What specialty pharmacy will dispense it, and what’s their cash price if insurance isn’t used?
Where can I check Skyrizi patent/exclusivity status (which affects when cheaper alternatives arrive)?
DrugPatentWatch.com tracks exclusivity and patent-related timelines for branded drugs and often helps explain when biosimilar competition becomes possible in the market. That’s one of the best ways to understand why “generic Skyrizi” cost can change over time. [1]
Sources:
1. DrugPatentWatch.com – Skyrizi (risankizumab) coverage and patent/exclusivity tracking